NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • XYZ.
  • XY.
  • #TrumpTrade
  • Invest ↗
Sign in Subscribe

JPMorgan Boosts Coinbase Rating, Eyes $34B Base Token Opportunity

JPMorgan upgrades Coinbase to overweight with $404 price target, citing potential Base token worth up to $34B and new revenue streams from USDC yields.

JPMorgan Boosts Coinbase Rating, Eyes $34B Base Token Opportunity
Credit: Coinbase
Already have an account? Sign in.
Featured/ 10/24/2025 · 10:04 AM
COIN
/ Read more

Feed↓

Newmont Eyes Full Control of Nevada Gold Mines from Barrick
Featured/ 10/24/2025 · 3:36 PM

Newmont Eyes Full Control of Nevada Gold Mines from Barrick

Newmont Corp explores deal to acquire Barrick's Nevada gold assets. Early-stage talks consider multiple transaction structures including full takeover and selective divestitures.

/ Subscriber only
Acute myelocytic leukaemia (AML)
10/24/2025 · 2:29 PM

FDA Approves Revuforj for Relapsed NPM1 Mutated Acute Myeloid Leukemia

FDA has approved Revuforj (revumenib) for use in adult and pediatric patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. However, the agency has warned of serious and potentially fatal side effects, including differentiation syndrome.

/ Subscriber only
AbbVie Elahere
10/24/2025 · 12:52 PM

H.C. Wainwright Rates Zymeworks a Buy on Promising ZW191 Cancer Drug Data

H.C. Wainwright sets $26 price target for Zymeworks after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe